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PURPOSE. Although recent studies have shown that macular pigment (MP) is significantly lower
in glaucoma patients, this relationship merits further investigation.
METHODS. This cross-sectional study included 85 glaucoma patients and 22 controls. All
subjects had standard automated perimetry (SAP) and retinal nerve fiber layer (RNFL)
thickness measurements. Intake of lutein (L) and zeaxanthin (Z) was estimated using a novel
dietary screener. The Heidelberg Spectralis dual-wavelength autofluorescence (AF) technol-
ogy was employed to study the relationship between MP and glaucoma. The association
between MP volume and glaucoma was investigated using linear regression models
accounting for potential confounding factors.
RESULTS. Glaucoma patients had significantly worse SAP mean deviation (MD) and lower RNFL
thickness in the study eye compared to control subjects (P < 0.001 for both). MP (volume)
was comparable between groups (P ¼ 0.436). In the univariable model, diagnosis of
glaucoma was not associated with MP volume (R2 ¼ 1.22%; P ¼ 0.257). Dietary intake of L
and Z was positively and significantly related to MP in the univariable (P ¼ 0.022) and
multivariable (P ¼ 0.020) models.
CONCLUSIONS. These results challenge previous studies that reported that glaucoma is
associated with low MP. Dietary habits were found to be the main predictor of MP in this
sample. Further research is merited to better understand the relationship between glaucoma,
MP, and visual performance in these patients.
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Glaucoma is a group of optic neuropathies that have incommon a progressive degeneration of retinal ganglion
cells (RGCs) and their axons, resulting in a characteristic
appearance of the optic disc and a concomitant pattern of
visual field loss.1 Assessment and estimation of the extent of the
disease have been traditionally made using standard automated
perimetry (SAP) and retinal nerve fiber layer (RNFL) measure-
ments through optical coherence tomography (OCT).
In addition, previous studies have recognized that glau-
comatous damage also affects macular structures.2–4 Therefore,
evaluation of macular components may be a valuable method of
assessment of the disease. In fact, approximately 50% of RGCs
are located within 4.5 mm (168) of the foveal center, a region
that represents only 7.3% of the total retina area.5 Further, the
macula is vital for central vision, and therefore, loss of macular
RGCs is likely to be of particular importance for vision-related
quality of life.
The macular carotenoids lutein (L), zeaxanthin (Z), and
meso-zeaxanthin (MZ) selectively accumulate in the central
retina (macula lutea), where they are collectively referred to as
macular pigment (MP).6,7 The anatomic (central and prerecep-
torial location), biochemical (antioxidant and anti-inflammato-
ry), and optical (short-wavelength [blue] light-filtering)
properties of the macular carotenoids make these ideal
candidates to enhance visual function,8 a hypothesis that has
been confirmed in subjects free of retinal disease,9 and in
patients with early (nonvisually consequential) age-related
macular degeneration (AMD).10 AREDS2, a study that examined
the role of supplementation of co-antioxidants in combination
with L and Z, reported a favorable effect for patients with
intermediate AMD by reducing the progression to advanced
forms of the disease.11 Further, Akuffo et al.12 demonstrated
that supplementation with L, Z, and MZ resulted in significant
increases in MP and improvements in contrast sensitivity and
other measures of visual function in patients with nonadvanced
AMD (1–8 on the AREDS 11-step severity scale).
To date, four studies have shown that MP is significantly
lower in patients with open-angle glaucoma compared to
control subjects.13–16 Of note, in those studies, MP was
measured using either the one-wavelength fundus reflectance
method15 or customized heterochromatic flicker photometry
(cHFP).13,14 However, the reflectance method used is limited
because it uses only one wavelength, and therefore does not
account for lens absorption.17 In addition, accurate measures of
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reflectance assume that retinal pigment epithelium melanin
and other light absorbers have the same distribution across the
retina. The cHFP technique, commonly referred to as the gold
standard for measuring MP, is a psychophysical technique and
therefore influenced by the operator’s implementation of the
test and subjects’ performance (i.e., their ability to take
instructions to eliminate flicker using different-sized targets).18
Also, this technique is time-consuming, and measuring a spatial
profile of MP can take up to 30 minutes per eye, with subject
fatigue making this test difficult to complete for some subjects,
especially so in patients with visual field loss (e.g., glaucoma
patients).
In our study we have taken advantage of recent application
of the Heidelberg Spectralis (HRAþOCT Multicolor) for
measuring MP objectively using dual-wavelength autofluores-
cence (AF) (see below for description of methods). Here, we
report on MP profiles in patients with glaucoma and healthy
control subjects, and investigate the relationship between MP
and visual function in these groups.
METHODS
This was a cross-sectional study that included participants from
a prospective longitudinal study designed to evaluate optic
nerve structure and visual function in glaucoma, the Diagnostic
Innovations in Glaucoma Study (DIGS). The study was
conducted at the Hamilton Glaucoma Center and Shiley Eye
Institute of the Department of Ophthalmology, University of
California San Diego (UCSD). Participants were longitudinally
evaluated according to a preestablished protocol that included
regular follow-up visits in which patients underwent clinical
examination and several other imaging and functional tests.
Methodologic details have been described previously.19 Writ-
ten informed consent was obtained from all participants, and
institutional review board and human subjects committee
approved all methods. All methods adhered to the tenets of the
Declaration of Helsinki for research involving human subjects,
and the study was conducted in accordance with the
regulations of Health Insurance Portability and Accountability
Act.
All participants underwent comprehensive ophthalmologic
examination including review of medical history, visual acuity
measured using the Early Treatment Diabetic Retinopathy
Study chart (letter acuity was expressed as the logarithm of
minimum angle of resolution), contrast sensitivity (CS)
assessment using the Pelli-Robson contrast sensitivity chart
(Precision Vision, La Salle, IL, USA), slit-lamp biomicroscopy,
intraocular pressure measurement, gonioscopy, stereoscopic
optic disc photography, and SAP using Swedish Interactive
Threshold Algorithm Standard with 24-2 strategy of the
Humphrey Field Analyzer II-i, model 750 (Carl Zeiss Meditec,
Inc., Dublin, CA, USA). Visual acuity was measured using the
Early Treatment Diabetic Retinopathy Study chart, and letter
acuity was expressed as the logarithm of minimum angle of
resolution. Only subjects with open angles on gonioscopy
were included. Subjects were excluded if they presented any
other ocular or systemic disease that could affect optic nerve
or visual field.
Two participant groups were included in the study as
follows: case participants (patients with confirmed presence of
glaucoma, see below) and control participants (subjects free of
glaucoma). Inclusion criteria were as follows: Glaucoma was
defined by the presence of repeatable abnormal SAP tests
(pattern standard deviation with P < 0.05 and/or a Glaucoma
Hemifield Test outside normal limits) and corresponding optic
nerve damage in at least one eye. Control subjects had no
evidence of optic nerve damage and had normal SAP tests in
both eyes. Controls were recruited from the general popula-
tion through advertisements and from staff and employees of
UCSD. All visual fields were evaluated by the UCSD Visual Field
Assessment Center (VisFACT).20 Only reliable SAP tests were
included (less than 33% fixation losses or false-negative errors,
and less than 15% false-positive errors). They were also
reviewed for artifacts, fatigue, or learning effects, inappropriate
fixation, evidence that the visual field results were caused by a
disease other than glaucoma (e.g., homonymous hemianopia)
and inattention; tests were excluded if such artifacts were
present.
All subjects had measurements of weight and height
obtained at the time of testing. These were used to calculate
body mass index (BMI) for each subject, as the quotient of
mass (in kilograms) divided by the square of height (in meters).
Spectral-Domain Optical Coherence Tomography
(SD-OCT)
Spectralis SD-OCT (software version 5.4.7.0; Heidelberg
Engineering, Dossenheim, Germany) was used to measure
peripapillary RNFL thickness in the present study. The device
uses a dual-beam SD-OCT and a confocal laser-scanning
ophthalmoscope (cSLO) that employs a super-luminescent
diode light with a center wavelength of 870 nm and an infrared
scan to provide simultaneous images of ocular microstructures.
A real-time eye tracking system is incorporated that couples
the cSLO and SD-OCT scanners to adjust for eye movements
and to ensure that the same location of the retina is scanned
over time. For RNFL thickness a total of 1536 A-scan points
were acquired from a 3.45-mm circle centered on the optic
disc. All images were reviewed by UCSD Imaging Data
Evaluation and Analysis Center to ensure the scan was
centered, that the signal strength was more than 15 decibels
(dB), and that there were no artifacts. Scans that were inverted
or clipped or those that showed coexistent retinal pathologic
abnormalities were excluded. The accuracy of the segmenta-
tion of each retinal layer also was checked for errors. The SD-
OCT RNFL thickness parameter used in the study was the
global RNFL thickness corresponding to the average of all
measures in the peripapillary circle.
Dietary and Supplement Carotenoid Assessment
Dietary intake of L and Z was estimated using a crude
carotenoid screener known as the ‘‘L/Z screener’’ developed by
Elizabeth Johnson (Tufts University, Boston, MA, USA). This
screener gives a dietary score (from 0 to 75), which can be
categorized as follows: estimate low intake, category 1: 0 to 15
(2 mg/day); estimate medium intake, category 2: 16 to 30 (3–
13 mg/day); estimate high intake, category 3: 31 to 75 (>13
mg/day). This tool has been described in detail elsewhere.21,22
Due to sample size, subjects with low and medium intake were
combined in subsequent analysis.
In addition, patients were asked if they were consuming any
commercially available food supplements. If participants
answered yes, the researchers queried the supplement brand
in order to investigate if the supplement contained L, Z, and/or
MZ. Supplementation use, defined as recent consumption of a
food supplement containing L, Z, and/or MZ, was coded as no
or yes for analyses.
Measurement of Macular Pigment
MP was measured using the Spectralis HRAþOCT Multicolor
(Heidelberg Engineering, Heidelberg, Germany) based on a
previously described protocol.18,23 In brief, the protocol used
20 3 15 volume scans, 19 scans each 239 lm apart at high
Macular Pigment in Patients With Glaucoma IOVS j September 2018 j Vol. 59 j No. 11 j 4472
speed, ART of 8 frames per B-scan. The Spectralis has a cSLO
with diode lasers and uses a dual-wavelength AF technique for
measuring MP. Dual-wavelength AF in this device uses two
excitation wavelengths, one that is well absorbed by MP (488
nm, blue) and one that is not well absorbed by MP (518 nm,
green). The excitation spectrum of the two different AF images
is then compared, and, along with a parafoveal reference point,
is used to calculate an MP density profile.
One eye measurement was acquired for each patient. The
eye considered for analysis was randomly selected for testing.
During the measurement, the patient’s head was positioned
with the help of the canthus alignment mark and forehead and
chin rest. The patient was then instructed to fixate on an
internal fixation target. Initial camera alignment, illumination,
and focus were done in infrared (IR) mode. Once the image
was evenly illuminated, the camera mode was switched to
simultaneous blue AF and green AF imaging (BAFþGAF) mode
for MP measurement acquisition. After additional adjustments
to illumination and focus, in order to ensure optimal image
quality, a 30-second video was recorded.
The AF images in the video were aligned and digitally
subtracted using HEYEX software, generating the MP spatial
distribution profile. MP at 0.238 and MP volume were recorded,
with the parafoveal reference set at 78. MP volume (MP average
times the area under the curve out to 78 eccentricity) was
calculated for our primary outcome measure.
Statistical Analysis
Descriptive statistics included mean and standard deviation of
the variables. Normality assumption was assessed by inspec-
tion of histograms and using Shapiro-Wilk test. Fisher’s exact
test was used for group comparison for categorical variables.
Student’s t-test was used for group comparison for normally
distributed variables and Wilcoxon rank-sum (Mann-Whitney)
test was used for group comparison for continuous non-
normally distributed variables.
The association between MP volume and diagnosis of
glaucoma was investigated using linear regression models,
where MP volume was used as dependent variable and
glaucoma diagnosis as independent variable. We initially ran
univariable models evaluating the association of each variable
with the outcome. Subsequently, multivariable models were
used, adjusting for potential confounding factors such as age,
BMI, and dietary intake of L and Z. All statistical analyses were
performed using commercially available software Stata, version
14 (StataCorp LP, College Station, TX, USA). The a level (type I
error) was set at 0.05.
RESULTS
The study included 85 glaucoma patients and 22 control
subjects. Table 1 presents demographic and clinical character-
istics of participants for each group, and whether the groups
were statistically similar or different. In brief, groups were
statistically comparable in age (P ¼ 0.414), but there was a
lower percentage of females in the glaucoma group compared
with the control group (50.6% vs. 77.3%, respectively; P ¼
0.030). There was no significant difference in race, BMI, visual
acuity, or contrast sensitivity of studied eye between groups. As
expected, glaucoma subjects had significantly worse SAP mean
deviation (MD) results in the studied eye when compared to
control subjects (6.4 6 7.4 dB vs. 0.1 6 1.0 dB, respectively;
P < 0.001). Also, global RNFL thickness in the study eye of
glaucoma patients was significantly lower than in controls
(71.6 6 16.8 lm vs. 86.4 6 14.7 lm, respectively; P < 0.001).
MP (volume) was statistically comparable between glauco-
ma patients and controls (8716.6 6 3901.8 vs. 7660.0 6
3750.2, respectively; P ¼ 0.436), even after controlling for
dietary intake of L and Z and carotenoid supplement use.
Table 2 presents univariable and multivariable linear
regression models for explaining MP volume. Again, in the
univariable model, diagnosis of glaucoma was not associated
with MP volume (R2¼ 1.22%; P¼ 0.257). Age, sex, race, visual
acuity, contrast sensitivity, SAP MD, and OCT RNFL were also
not statistically significantly associated with MP volume.
Subjects with higher BMI had an association close to
significance with lower MP volume (R2 ¼ 3.59%; P ¼ 0.052).
High dietary intake of L and Z had a statistically significant
association with MP volume in the univariable (R2¼ 4.92%; P¼
0.022) and multivariable (P ¼ 0.020) models.
DISCUSSION
Over the last two decades there has been growing interest in
the role of the macular carotenoids for visual performance (in
diseased and nondiseased eyes) and for prevention of
AMD.9,12,24,25 These nutrients are now also being studied for
their potential role to enhance cognitive function, with
promising initial findings.26 This study, however, was designed
to compare MP measurements in glaucoma patients to
controls, and to investigate the association between MP and
visual function in these groups.
Our study demonstrated no association between MP and
glaucoma diagnosis. Also, we did not find any association
between MP and variables that are usually used to assess and
estimate the extent of glaucoma, such as SAP and SD-OCT.
Although we did identify that MP was related to dietary L and Z
intake (i.e., via diet and/or food supplements), controlling for
dietary intake of L and Z did not alter our main finding (i.e.,
that MP was not related to glaucoma status). Of note, our
finding that dietary intake of L and Z is related to MP levels is
consistent with the exclusive dietary origin of these nutrients
and a recent meta-analysis that confirmed a dose–response
TABLE 1. Demographic and Clinical Characteristics of Subjects
Included in the Study*
Characteristics
Glaucoma,
n ¼ 85
Controls,
n ¼ 22
P
Value
Age, y 72.5 6 10.1 70.0 6 10.3 0.414†
Sex, n (%) female 43 (50.6) 17 (77.3) 0.030‡
Race, n (%) 0.945‡
White 57 (67.1) 16 (72.7)
African American 18 (21.2) 5 (22.7)
Asian 7 (8.2) 1 (4.6)
Other 2 (2.4) 0 (0)
BMI, kg/m2 26.6 6 5.8 29.1 6 5.6 0.053†
MP volume 8716.6 6 3902.8 7660.6 6 3750.2 0.436†
Central MP, 0.238 0.52 6 0.19 0.49 6 0.18 0.543§
Diet, estimated L
and Z intake
30.1 6 13.3 36.3 6 14.4 0.056§
Carotenoid supplement,
n (%) yes
26 (30.6) 6 (27.3) 0.762‡
Visual acuity, logMAR 0.04 6 0.14 0.03 6 0.12 0.410†
Contrast sensitivity 1.40 6 0.30 1.53 6 0.13 0.066†
SAP 24-2 MD, dB 6.4 6 7.4 0.1 6 1.0 <0.001†
RNFL thickness, lm 71.6 6 16.8 86.4 6 14.7 <0.001§
logMAR, logarithm of the minimum angle of resolution.
* Values are presented as mean 6 standard deviation, unless
otherwise noted.
† Wilcoxon rank-sum test.
‡ Fisher’s exact test.
§ Student’s t-test
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relationship between dietary/supplement intake of L, Z and
MZ, and MP levels.27
Interestingly, these results demonstrated that mean diet
scores, obtained using the L/Z screener, were much higher in
the San Diego glaucoma population compared with an Irish
glaucoma population. Nolan et al.22 in a recent study
performed in Waterford (Ireland) reported a diet score of 24
(3–13 mg/day) in the sample (of similar age) studied, compared
with a score of 36 (>13 mg/day) in the current sample. This
finding suggests that the participants from the San Diego
population consume, on average, more L and Z (estimated
combined). Of note, the differences seen in dietary intake of
these carotenoids was also reflected in the MP data, with the
average MP volume score in the San Diego population of 7660
compared to the Irish population of 6326.
Four earlier studies have suggested that MP may have an
important role in glaucoma. These studies reported that
glaucoma patients tend to have lower MP values compared
to control subjects (see Table 3).13–15 However, results from
the current study are not in agreement with these earlier
reports, because MP levels in glaucoma patients were not
significantly different from those in the control group. First, we
acknowledge that the glaucoma patients in our study were
older than patients from the previous reports. However, we
feel that this is unlikely to explain our findings, as MP is not
related to age.28,29 Secondly, the patients in the current study
had higher BMIs compared to the other studies, and we know
that MP is inversely related to BMI, since adipose tissue acts as
a storage/reservoir for carotenoids and may therefore compete
with the retina for the uptake of the macular carotenoids.30,31
However, although our population had higher BMI values, they
also exhibited higher MP values compared to the other studies,
probably due to dietary differences between the populations as
discussed above.
Our study also demonstrated no significant relationship
between MP and the gold standard tests used to evaluate
glaucoma, that is, SAP MD and SD-OCT RNFL. Ji et al.15 and
Igras et al.13 also did not find significant associations between
SAP MD and MP. Although Siah et al.14 did not report on the
relationship between SAP MD and MP, in a more recent study
from their group based on the same population, they reported
that MP was significantly correlated with SAP MD results.16
When referring to RNFL profile, Ji et al.15 and Siah et al.14 did
not find any association with MP, and these findings are
consistent with our work. Of note, Ji et al.15 and Igras et al.13
did not assess dietary intake of L and Z in their studies, and
therefore interpretation of their findings must take this
limitation into consideration.29
Previous reports have documented CS losses in glaucoma
patients, even when presenting a relatively good visual
acuity.32 Loughman et al.33 have demonstrated that an increase
in MP resulted in significant improvements in CS. The
anatomic (central and prereceptorial location), biochemical
(antioxidant and anti-inflammatory), and optical (short-wave-
length [blue] light-filtering) properties of the macular caroten-
oids make these ideal candidates to enhance visual function,
and therefore MP measurements in glaucoma patients might be
valuable due to the disease characteristics and symptoms that
typically result with a loss of visual function. In addition, future
studies should be performed in order to evaluate the role of
specific carotenoid supplementations on visual function in
glaucoma patients.
Our study had limitations. Due to the cross-sectional design,
we were not able to clearly determine the temporal
relationship between MP measurement and carotenoid sup-
plement intake. It is also important to acknowledge that our
case/control design has limitations given that the ratio of cases
to controls is 1:3.8. It is known that the statistical confidence in
a case–control design increases with an increase in ratio of
TABLE 2. Results of the Univariable and Multivariable Linear Regression Models for Explaining Macular Pigment Volume*
Characteristic
Univariable Model Multivariable Model
Coefficient (95% CI) P Coefficient (95% CI) P
Glaucoma 1056.0 (780.8 to 2892.9) 0.257 954.96 (908.86 to 2818.78) 0.312
Diet, high L and Z intake 1719.3 (257.5 to 3181.1) 0.022 1775.59 (290.16 to 3261.03) 0.020
Age, per decade older 323.0 (415.3 to 106.1) 0.388 393.89 (333.74 to 1121.53) 0.285
Sex, female 413.7 (1089.7 to 1916.1) 0.587
Race, African American 60.0 (758.2 to 1878.3) 0.948
BMI, per 1 kg/m2 higher 126.0 (252.9 to 0.9) 0.052 96.59 (224.07 to 30.88) 0.136
Visual acuity, per 0.1 logMAR higher 3122.0 (8482.7 to 2238.7) 0.251
Contrast sensitivity 1148.1 (3746.0 to 1449.8) 0.383
MD SAP 24-2, per 1 dB lower 11.5 (17.5 to 94.5) 0.830
OCT RNFL thickness, per 1 lm thinner 9.2 (53.1 to 34.8) 0.681
CI, confidence interval.
* Multivariable model was adjusted for age, BMI, and dietary carotenoid intake.
TABLE 3. Clinical Characteristics of Studies Demonstrating Relantionship Between Macular Pigment Optical Density (MPOD) and Glaucoma*
Reference Age, y Population BMI Diagnosis MP
Present study† 72.8 6 11 60.7% Caucasian 27 6 6.1 POAG 0.52 6 0.19
Igras et al.13‡ 69.0 6 11 N/R N/R 90% POAG 0.23
Siah et al.14‡ 67 N/R 25.5 51.1% POAG 0.23
Ji et al.15§ 42.3 6 16.9 Chinese 22.2 6 2.5 POAG 0.116
POAG, primary open-angle glaucoma; N/R, not reported.
* Values are presented as mean 6 standard deviation, unless otherwise noted.
† MPOD was measured through physical (objective) dual-wavelength autofluorescence.
‡ MPOD was measured using customized heterochromatic flicker photometry.
§ MPOD was measured using one-wavelength fundus reflectance.
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control to case participants up to 4:1, beyond which there is
no more benefit; therefore our design falls significantly short of
the optimal scenario. In addition, we were not able to
investigate the longitudinal relationship between SAP MD
and SD-OCT RNFL measurements with MP. Future longitudinal
studies should be able to clarify this issue. Although SAP is the
gold standard for glaucoma functional assessment, due to its
simplicity it is likely that it does not fully capture certain
dynamic aspects of vision that may be important in performing
daily activities, such as driving, reading, or navigating the
environment. Previous studies have demonstrated that patients
with glaucoma had a higher incidence of motor vehicle
collisions34,35 and performed worse on wayfinding tasks.36
Therefore future studies should be performed in order to
evaluate the relationship between MP and driving and/or
navigating the environment. We did not report cataract status
of our population, and MP measurements obtained via dual-
wavelength AF are known to be influenced by cataract
status.37 In addition, we did not report smoking or cognitive
status from the population studied and these could have
impacted MP measurements. However, it is unlikely that this
could have influenced the main conclusions of the study.
In conclusion, patients diagnosed with glaucoma in this
study had comparable MP levels to control subjects. Our
results disagree with previous studies reporting on MP in
patients with glaucoma. However, it is our view that there is no
explicit reason as to why patients with glaucoma would be
lacking in MP levels compared to controls. Although not tested
in our study, we do believe (based on a biologically plausible
rationale and many published clinical trials) that enrichment of
MP may be important to enhance visual function in patients
with glaucoma. Further research is merited to better under-
stand the relationship between glaucoma and macular carot-
enoids, and the impact of enriching these nutrients in these
patients.
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